Peter Dubsky, MD, PhD, will moderate a Tuesday morning session looking at how new and emerging research findings are impacting best practices in localized breast cancer therapy.

Virginia Kaklamani, MD, DSc, leads a panel discussion on Tuesday looking at the predictive value of neoadjuvant treatment response in ER+, HER2+, and triple negative breast cancer patients.